Silver Book Fact

For beneficiaries with wet age-related macular degeneration (AMD), annual Medicare part B payments for vision care increased from $1,504 per beneficiary in 1994 to $3,263 in 2006–due in large part to anti-VEGF treatments.

Day, Shelley, Kofi Acquah, Paul P. Lee, Prithvi Mruthyunjaya, and Frank A. Sloan. Medicare Costs for Neovascular Age-Related Macular Degeneration, 1994-2007. Ophthalmol. May 2011; 152(6): 1014-20. http://www.ajo.com/article/S0002-9394%2811%2900410-7/abstract

Reference

Title
Medicare Costs for Neovascular Age-Related Macular Degeneration, 1994-2007
Publication
Ophthalmol
Publication Date
May 2011
Authors
Day, Shelley, Kofi Acquah, Paul P. Lee, Prithvi Mruthyunjaya, and Frank A. Sloan
Volume & Issue
Volume 152, Issue 6
Pages
1014-20
URL
Read Full Resource

Categories

  • Cost of Disease
  • Economic Burden

Related Facts

  • The excess economic burden of visual impairment and blindess of individuals age 40 and older on the individual, caregivers, and other health care payers is an estimated $5.48 billion annually–…  
  • Risk of DR
    The risk of DR increases the longer a person has diabetes.  More than 75% of people who have diabetes for more than 20 years will have some form of DR.  
  • An estimated 424,801 more visually impaired and blind individuals live in nursing homes than would be expected if they had normal vision.  
  • An estimated 79,268 Americans ages 50-54 have age-related macular degeneration (AMD). That grows to 231,373 at ages 75-79 and more than 1.3 million for ages 80+.  
  • Visual loss from subfoveal choroidal neovascularization, a characteristic of wet age-related macular degeneration (AMD), was found to have a profound impact on how patients felt about their health-related quality of…